{
    "clinical_study": {
        "@rank": "80547", 
        "arm_group": [
            {
                "arm_group_label": "ELAD (plus Standard of Care)", 
                "arm_group_type": "Experimental", 
                "description": "ELAD  is a cellular, extracorporeal, liver assist system. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines."
            }, 
            {
                "arm_group_label": "Standard of Care (Control)", 
                "arm_group_type": "Other", 
                "description": "Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD.EASL Guidelines."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if treatment with the ELAD System is safe and\n      effective in subjects with severe acute alcoholic hepatitis who have failed steroid therapy."
        }, 
        "brief_title": "A Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Alcoholic Hepatitis Who Have Failed Steroid Therapy", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Acute Alcoholic Hepatitis", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis, Alcoholic", 
                "Hepatitis", 
                "Hepatitis A"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects with severe acute alcoholic hepatitis (sAAH) are often treated with steroids as\n      soon as their diagnosis is confirmed.  This study is to assess treatment with the ELAD\n      System in subjects where the steroid treatment has failed.  ELAD treatment is done\n      continuously for up to 10 days in addition to standard of care treatment.  The Control group\n      (those chosen not to receive ELAD treatment) will also get standard of care treatment.\n      Standard of care is defined as the usual care for diet, medications, treatment of\n      complications that may arise, etc. for sAAH patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 ;\n\n          -  Total bilirubin \u2265 8 mg/dL;\n\n          -  A clinical diagnosis of acute alcoholic hepatitis (AAH), confirmed by liver biopsy;\n\n          -  Subject must have failed steroid therapy according to Lille protocol (Lille score >\n             0.45) after at least 7 and not more than 9 days of steroid therapy.\n\n        Exclusion Criteria:\n\n          -  Platelet count < 50,000/mm3;\n\n          -  International Normalization Ratio (INR) > 3.0;\n\n          -  Evidence of infection unresponsive to antibiotics;\n\n          -  Evidence of more than one steroid regimen during this episode of liver failure;\n\n          -  Hospital admission for any episodes of liver decompensation within the past 2 months;\n\n          -  On mechanical ventilation;\n\n          -  Evidence of hemodynamic instability;\n\n          -  Evidence of active bleeding or of major hemorrhage;\n\n          -  Evidence of variceal bleeding within 7 days of Screening;\n\n          -  Evidence of occlusive portal vein thrombosis, or evidence of bile duct obstruction;\n\n          -  Evidence by physical exam, history, or laboratory evaluation of significant\n             concomitant disease with expected life expectancy of less than 3 months;\n\n          -  Chronic end-stage renal disease requiring chronic hemodialysis for more than 8 weeks\n             (not classified as hepatorenal syndrome);\n\n          -  Uncontrolled seizures;\n\n          -  Positive serologies for viral hepatitis B or C;\n\n          -  Pregnancy or lactation;\n\n          -  Participation in another investigational drug, biologic, or device study within one\n             month of enrollment, except for observational studies;\n\n          -  Previous liver transplant;\n\n          -  Previous participation in a clinical trial involving ELAD;\n\n          -  Foreseeable eligibility for liver transplant during the 90-day study period;\n\n          -  Has a Do Not Resuscitate or a Do Not Intubate (DNR/DNI) directive (or local\n             equivalent) or any other Advanced Directive limiting Standard of Care in place;\n\n          -  Inability to provide an address for follow-up home health visits\n\n        And other inclusion/exclusion criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829347", 
            "org_study_id": "VTI-210"
        }, 
        "intervention": [
            {
                "arm_group_label": "ELAD (plus Standard of Care)", 
                "description": "ELAD is an extracorporeal system that runs blood(plasma) through liver cells outside the body.", 
                "intervention_name": "ELAD", 
                "intervention_type": "Biological", 
                "other_name": "Liver assist system"
            }, 
            {
                "arm_group_label": [
                    "ELAD (plus Standard of Care)", 
                    "Standard of Care (Control)"
                ], 
                "description": "Standard of care is predefined treatment for AAH complications (ascites, hepatic encephalopathy, varices, etc.)", 
                "intervention_name": "Standard of Care treatment", 
                "intervention_type": "Other", 
                "other_name": "Usual treatment for the disease"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Liver failure", 
            "acute alcoholic hepatitis", 
            "patients failing steroid therapy"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "link": {
            "url": "http://www.vitaltherapies.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "CABALLER@clinic.ub.es", 
                    "last_name": "Juan Caballeria, MD", 
                    "phone": "+34 93 227 17 13"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic de Barcelona"
                }, 
                "investigator": {
                    "last_name": "Juan Caballeria, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jlm14005623@gmail.com", 
                    "last_name": "Jos\u00e9 Lu\u00eds Montero, MD", 
                    "phone": "+34 957 01 03 28"
                }, 
                "facility": {
                    "address": {
                        "city": "Cordoba", 
                        "country": "Spain", 
                        "zip": "14004"
                    }, 
                    "name": "Hospital Reina Sofia"
                }, 
                "investigator": {
                    "last_name": "Jos\u00e9 Lu\u00eds Montero, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rbanares@telefonica.net", 
                    "last_name": "Rafael Ba\u00f1ares, MD", 
                    "phone": "+34 91 586 86 99"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "Hospital Gregorio Mara\u00f1on"
                }, 
                "investigator": {
                    "last_name": "Rafael Ba\u00f1ares, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "melrose.browne-morgan@nhs.net", 
                    "last_name": "Melrose Browne-Morgan", 
                    "phone": "+44 020 7794 0500", 
                    "phone_ext": "22522"
                }, 
                "contact_backup": {
                    "email": "nicola.childs@nhs.net", 
                    "last_name": "Nicola Childs, RN", 
                    "phone": "+44 020 7794 0500", 
                    "phone_ext": "22522"
                }, 
                "facility": {
                    "address": {
                        "city": "Hampstead", 
                        "country": "United Kingdom", 
                        "state": "London", 
                        "zip": "NW3 2QR"
                    }, 
                    "name": "Royal Free Hospital"
                }, 
                "investigator": {
                    "last_name": "Rajiv Jalan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD\u00ae in Subjects With Acute Alcoholic Hepatitis (AAH) Who Have Failed Steroid Therapy", 
        "overall_contact": {
            "email": "ahenry@vitaltherapies.copm", 
            "last_name": "Andrew Henry", 
            "phone": "858-673-6840", 
            "phone_ext": "1844"
        }, 
        "overall_contact_backup": {
            "email": "mstephens@vitaltherapies.com", 
            "last_name": "Michael Stephens", 
            "phone": "858-924-1991"
        }, 
        "overall_official": [
            {
                "affiliation": "Vital Therapies, Inc.", 
                "last_name": "Jan Stange, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Royal Free Hospital NHS Foundation Trust", 
                "last_name": "Rajiv Jalan, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Clinic de Barcelona", 
                "last_name": "Juan Caballeria, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Reina Sofia", 
                "last_name": "Jos\u00e9 Luis Montero, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Gregorio Mara\u00f1on", 
                "last_name": "Rafael Ba\u00f1ares, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Research Ethics Committee", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall survival of subjects will be assessed from study randomization (Day 1) through Study Day 91.", 
            "measure": "Overall survival at Day 91", 
            "safety_issue": "Yes", 
            "time_frame": "Study Day 1 through Study Day 91"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate the proportion of survivors at Study Days 28 and 91.", 
            "safety_issue": "No", 
            "time_frame": "Study Days 28 and 91."
        }, 
        "source": "Vital Therapies, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vital Therapies, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}